Best Neurology Companies in Pennsylvania, United States

Developer of gene therapy medicines for neurological diseases. The company leverages precision delivery through Adeno-Associated Virus to target specific cells and tissues, to improve the lives of patients suffering from various central nervous system disorders.

Funding rounds

• May 2026Series A$97M
• May 2024Series A$54M

Founders & team

P GhoroghchianCEO

Investors

8VC, DCVC, Children's Hospital of Philadelphia, Ben Franklin Technology Partners, Gaingels, Modi Ventures

Developer of therapeutics to treat psychiatric diseases. The company focuses on the development of drugs for CNS and cannabis withdrawal syndrome that causes severe emotional, psychiatric, and physical illness.

Funding rounds

• Oct 2025Series B$36M
• Jun 2025Series B$6.2M
• May 2022Series B$11.1M

Founders & team

Jay ConstantineCo-FounderGinger ConstantineCo-Founder & CEO

Investors

Purchase Capital

Developer of genetic tests for personalised medicines to enhance mental health treatment. It offers Genomind's PGx test that examines genes related to mental health treatment, providing insights into how a patient may metabolize or respond to different medication. It also offer Mental Health Map a DNA test that assesses genetic predispositions across core mental health capabilities, including mood, focus, and stress responses.

Funding rounds

• Feb 2025Grant (prize money)$399.6K
• Sep 2023Grant (prize money)$399.6K
• Apr 2021Series C$6.4M
• Jul 2018Series C$20.6M

Founders & team

Bill BrownCEO

Investors

SVB, Claritas Capital, HHS

Tech stack

AccessibeActivecampaignAll In One SeoAmazon SesAmazon Web ServicesBootstrap

Developing innovative therapeutics targeting protein degradation for challenging diseases. The company is focused on advancing a new class of medicine through Molecular Glues and targeted protein degradation. Their platform leverages the ubiquitin system to develop therapies for challenging diseases, including neurodegenerative diseases like Parkinson’s and Alzheimer’s, cardiovascular disorders, metabolic dysfunction, and aging-related conditions. The company is engaged in drug discovery, delivering a pipeline of first-in-class therapeutics. They are exploring partnerships to further their reach and impact in the pharmaceutical industry. Their research focuses on areas like mitochondria, the Ubiquitin Proteasome System (UPS), and phospho-ubiquitin to restore mitochondrial functions and address diseases. The company is committed to innovation and redefining treatment paradigms through targeted protein degradation.

Funding rounds

• May 2025Grant (prize money)$302.4K
• 2024Grant (prize money)$269.6K
• 2022Grant (prize money)$551.5K
• 2021Grant (prize money)$266K

Founders & team

Tauseef ButtPresident and CEO

Investors

HHS, Ben Franklin Technology Partners

Tech stack

WordpressMysqlPhpDiviYoast SeoNginx

Developer of therapeutics for the treatment of pain. The lead molecule MAX-001 is a non-opioid, non-NSAID analgesic, a centrally-acting agent with anti-nociceptive effects via neurotransmitter mechanism action. This is used for the treatment of surgery, acute and chronic pain.

Funding rounds

• Jun 2025Series A$900.2K
• May 2021Series A$5.6M

Founders & team

Shawn FatholahiCEO & President

Tech stack

WordpressMysqlPhpWp RocketApache Http ServerPriority Hints

Trevena is a developer of GPCR ligand technology-based therapeutics for cardiovascular diseases and pain. It has three programs in development: TRV027, currently in Phase 2 clinical testing for the treatment of acute heart failure; TRV130, currently completing phase 1 testing for the intravenous treatment of postoperative pain; and TRV734, currently in pre-clinical testing for oral treatment of acute and chronic pain. In addition, Trevena has built an early-stage portfolio of drug discovery programs currently in lead optimization.

Surgical solutions advancing nerve recovery, restoring hope after nerve injury. The company is dedicated to developing innovative surgical solutions to improve healing following nerve damage. They focus on creating transformative implantable technologies to help patients affected by peripheral nerve injury. Committed to making a real impact, the team approaches their work with rigor, evidence, and high standards. They value collective intelligence, transparency, and frank collaboration. The company believes in a future where nerve injury can be resolved with solutions that are simple, affordable, and available to all. Their mission-driven approach aims to provide the next generation of surgical interventions for nerve repair and pain management.

Funding rounds

• Sep 2025Grant (prize money)$1.3M
• Sep 2025Seed$324.8K
• Sep 2024Grant (prize money)$500K
• Jul 2024Seed$335K

Founders & team

Lorenzo SolettiCo-Founder

Investors

Defense.gov, NIH, America’s Seed Fund, HHS, National Science Foundation, McGovern Center

Tech stack

WixReactGoogle CloudPolyfillLodashPriority Hints

Developer of psychedelic-based therapeutics for mental health conditions. The drug candidates include MSD-101 for PTSD, MSD-201 for depression, and others. The company has an Osmanthus platform for the prediction of phenomenological psychedelic effects.

Funding rounds

• Nov 2024Series A$12.7M
• Feb 2022Seed$11.5M
• Sep 2021Seed$125K

Founders & team

Dillan DiNardoCEO

Investors

Y Combinator, Initialized Capital, Metaplanet, Negev Capital, Day One Ventures, Actions Capital

Tech stack

CloudflareGoogle AnalyticsGoogle Font ApiGoogle Hosted LibrariesGoogle WorkspaceHsts

Developer of neurological rehabilitation medical devices. HMT seeks to develop, license, and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Portable Neuromodulation Stimulator (PoNS) device is based on neuromodulation that is used in external stimulation to intentionally change and regulate the electrochemical environment of the brain. In clinical studies, the PoNS device coupled with targeted functional therapy induces cranial nerve noninvasive neuromodulation (CN-NINM). Therapy consists of targeted physical, occupational and cognitive exercises, based on the patient’s deficits.

Funding rounds

• Sep 2025Post IPO$500M
• Jan 2025Post IPO$3.7M
• Oct 2020Post IPO$3.4M
• Dec 2017Post IPO$1.7M

Founders & team

Dane AndreeffCEO & President

Investors

Pantera Capital, Summer Capital Management Company, Animoca Brands, FalconX, HashKey Capital, Avenir Growth Capital

Tech stack

Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAmazon Web Services

Developer of pharmaceuticals that repair the gut-brain axis to treat patients suffering from neurodegenerative diseases. Its lead compound, ENT-01 (kenterin), displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the enteric nervous system (ENS) and improves neural signaling between the gut and the brain in preclinical models of Parkinson’s disease. ENT-01 is being developed to reverse the constipation of Parkinson’s disease, multiple systems atrophy, Schizophrenia, and an Autism spectrum disorder.

Funding rounds

• Nov 2023Series B$5.1M
• Oct 2021Series B$5.7M
• Sep 2020Series B$11.7M
• Jan 2019Series B$16.7M

Founders & team

Michael ZasloffFounderDenise Barbut Md Frcp FcppCo-FounderDavid McCulloughCEO

Investors

Scientia Ventures, The Naissos Group

Knopp Biosciences is a developer of small-molecule therapeutics for the treatment of CNS and inflammatory diseases. It's lead candidate dexpramipexole targets mitochondrial function has completed phase II trials for hypereosinophilic syndrome, chronic rhinosinusitis and Amyotrophic lateral sclerosis. In addition, the company is evaluating further candidates for neuropathic pain and epilepsy.

Developer of meter-dosed spray & liposomal gels for topical pain management. The company is focusing on developing meter-dosed spray delivery for topical application of NSAIDs and an aerosol-based system that delivers API as a Patch-in-a-Can. Also, developing, local anesthetic liposomal gel, composed of encapsulated bupivacaine in hydrogel & lipids.